albendazole and Malaria, Falciparum

albendazole has been researched along with Malaria, Falciparum in 10 studies

Malaria, Falciparum: Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.

Research

Studies (10)

Authors

Clinical Trials (2)

Trial Overview

Trial Outcomes

Adverse Events

The number of adverse events. Adverse events data were collected via passive case detection from total population. (NCT02509481)
Timeframe: Approximately 18 weeks, from the start of the first MDA to 3 weeks following the last MDA in the Experimental arm

Entomological Indicator of Parasite Transmission

Change in human IgG reactivity (optical density; ∆OD) to an Anopheles salivary gland antigen (peptide gSG6-P1) over the trial period. A score of 0 indicates no change in seroreactivity from from immediately before to immediately after the trial, suggesting consistent mosquito biting throughout the trial. A positive score indicates increasing seroreactivity and thus increasing mosquito biting on participants from immediately before to immediately after the trial. A negative score indicates decreasing seroreactivity and thus decreasing mosquito biting on participants from immediately before to immediately after the trial. (NCT02509481)
Timeframe: Approximately 20 weeks, from before the start of the first MDA to 4 weeks following the last MDA in the Experimental arm

Entomological Inoculation Rate

The entomological inoculation rate (EIR per week per person) is the measure of the human biting rate per person per week, multiplied by the sporozoite rate (in biting mosquitoes) per week, an estimated from sampling mosquitoes from 8 households located in the center of each study village. The EIR was calculated for each of the 6 sampling weeks of the treatment phase. (NCT02509481)
Timeframe: 6 sampling periods over 18 weeks, starting in week 2 following the first MDA, and sampling every 3 weeks thereafter until week 17 of the treatment phase.

Incidence of Clinical Malaria Episodes

Cumulative incidence of malaria episodes in a cohort of village children ≤ 5 years of age (as assessed by active case surveillance in study villages - malaria episode defined as ≥38.0°C fever or history of fever in the last 24 hours + positive rapid diagnostic test for Plasmodium falciparum). Incidence is reported as malaria episodes per child over the course of the trial, a higher incidence is a worse outcome. (NCT02509481)
Timeframe: Approximately 18 weeks, from the start of the first MDA to 3 weeks following the last MDA in the Experimental arm

Molecular Force of P. Falciparum Infection

Examination of new P. falciparum clones acquired from the beginning to the end of the intervention (molecular force of infection; mFOI) per child. Molecular genotyping used capillary blood taken at the time of diagnosis of each positive malaria episode and consisted of nPCR of the msp2 gene. We calculated the multiplicity of infection (MOI) per malaria episode, and then calculated the molecular force of infection (mFOI) associated with malaria episodes per child (over course of the trial) (NCT02509481)
Timeframe: Approximately 18 weeks, from the start of the first MDA to 3 weeks following the last MDA in the Experimental arm

Number of 6-10 Year Old Participants With Soil Transmitted Helminths (STH)

Prevalence of soil transmitted helminth infections in children between 6-10 years old from the beginning to the end of the intervention (NCT02509481)
Timeframe: Approximately 20 weeks, from before the start of the first MDA to 4 weeks following the last MDA in the Experimental arm

Trials

5 trials available for albendazole and Malaria, Falciparum

Other Studies

5 other studies available for albendazole and Malaria, Falciparum